Tradewinds Capital Management LLC Purchases 124 Shares of Novo Nordisk A/S (NYSE:NVO)

Tradewinds Capital Management LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 2.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,984 shares of the company’s stock after purchasing an additional 124 shares during the period. Tradewinds Capital Management LLC’s holdings in Novo Nordisk A/S were worth $429,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 105.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 18,041 shares of the company’s stock worth $2,148,000 after acquiring an additional 9,272 shares during the last quarter. Tectonic Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 6.6% in the 3rd quarter. Tectonic Advisors LLC now owns 5,512 shares of the company’s stock valued at $656,000 after purchasing an additional 340 shares during the period. Capital Management Associates Inc boosted its position in shares of Novo Nordisk A/S by 3.7% during the third quarter. Capital Management Associates Inc now owns 3,299 shares of the company’s stock valued at $393,000 after purchasing an additional 119 shares in the last quarter. Country Club Bank grew its stake in Novo Nordisk A/S by 11.3% in the third quarter. Country Club Bank now owns 1,837 shares of the company’s stock worth $222,000 after purchasing an additional 187 shares during the period. Finally, Convergence Financial LLC lifted its position in Novo Nordisk A/S by 41.0% during the third quarter. Convergence Financial LLC now owns 11,151 shares of the company’s stock valued at $1,328,000 after buying an additional 3,243 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent research reports. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $88.07 on Friday. The company has a 50 day moving average of $86.01 and a 200 day moving average of $108.07. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The firm has a market cap of $395.19 billion, a P/E ratio of 26.77, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.